{"id":"etilevodopa","rwe":[{"pmid":"34609478","year":"2021","title":"Ocular Penetrance and Safety of the Dopaminergic Prodrug Etilevodopa.","finding":"","journal":"Translational vision science & technology","studyType":"Clinical Study"},{"pmid":"20021407","year":"2009","title":"Homology modeling of adenosine A2A receptor and molecular docking for exploration of appropriate potent antagonists for treatment of Parkinson's disease.","finding":"","journal":"Current aging science","studyType":"Clinical Study"},{"pmid":"16476809","year":"2006","title":"A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations.","finding":"","journal":"Archives of neurology","studyType":"Clinical Study"},{"pmid":"15298067","year":"2004","title":"Drugs in development for Parkinson's disease.","finding":"","journal":"Current opinion in investigational drugs (London, England : 2000)","studyType":"Clinical Study"},{"pmid":"14646613","year":"2003","title":"Pharmacokinetics of etilevodopa compared to levodopa in patients with Parkinson's disease: an open-label, randomized, crossover study.","finding":"","journal":"Clinical neuropharmacology","studyType":"Clinical Study"}],"tags":[{"label":"etilevodopa","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"N04BA06","category":"atc"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"levodopa ethyl ester","offLabel":[],"synonyms":["etilevodopa","levodopa ethyl ester"],"timeline":[],"approvals":[],"brandName":"Levodopa Ethyl Ester","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"etilevodopa","explanation":"Think of dopamine like a key that unlocks feelings of pleasure and motivation. When dopamine levels are low, people may experience symptoms like fatigue, depression, and difficulty moving. Etilevodopa helps increase dopamine levels, which can help alleviate these symptoms.","oneSentence":"Etilevodopa works by crossing the blood-brain barrier and increasing dopamine levels in the brain.","technicalDetail":"Etilevodopa is a prodrug of levodopa, which is converted into dopamine in the brain through a series of enzymatic reactions. This allows etilevodopa to bypass the blood-brain barrier and increase dopamine levels more efficiently than levodopa alone."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4422","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ETILEVODOPA","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T11:09:29.976491","biosimilars":[],"competitors":[{"drugName":"levodopa","drugSlug":"levodopa","fdaApproval":"1970-06-04","patentExpiry":"Oct 21, 2033","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"etilevodopa","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"levodopa","brandName":"levodopa","genericName":"levodopa","approvalYear":"1970","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"895X917GYE","CHEBI":"CHEBI:135971","INN_ID":"7818","RXNORM":"1421444","UMLSCUI":"C1434556","ChEMBL_ID":"CHEMBL1823681","KEGG_DRUG":"D04097","DRUGBANK_ID":"DB06535","PUBCHEM_CID":"170345","MESH_SUPPLEMENTAL_RECORD_UI":"C481190"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":6,"therapeuticAreas":["Hematology"],"atcClassification":{"source":"DrugCentral","atcCode":"N04BA06","allCodes":["N04BA06"]},"biosimilarFilings":[],"recentPublications":[{"date":"2021 Oct 4","pmid":"34609478","title":"Ocular Penetrance and Safety of the Dopaminergic Prodrug Etilevodopa.","journal":"Translational vision science & technology"},{"date":"2009 Jul","pmid":"20021407","title":"Homology modeling of adenosine A2A receptor and molecular docking for exploration of appropriate potent antagonists for treatment of Parkinson's disease.","journal":"Current aging science"},{"date":"2006 Feb","pmid":"16476809","title":"A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations.","journal":"Archives of neurology"},{"date":"2004 Jul","pmid":"15298067","title":"Drugs in development for Parkinson's disease.","journal":"Current opinion in investigational drugs (London, England : 2000)"},{"date":"2003 Nov-Dec","pmid":"14646613","title":"Pharmacokinetics of etilevodopa compared to levodopa in patients with Parkinson's disease: an open-label, randomized, crossover study.","journal":"Clinical neuropharmacology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Etilevodopa, also known as Levodopa Ethyl Ester, is a small molecule drug in the etilevodopa class. Its exact target is unknown, but it is believed to work by crossing the blood-brain barrier and increasing dopamine levels in the brain. Etilevodopa is not FDA-approved for any indications, and its commercial status, patent status, and availability of generic manufacturers are also unknown. As a result, there is limited information available on its safety profile and efficacy. Further research is needed to fully understand the potential benefits and risks of etilevodopa.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}